Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DaVita (DVA) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Why DaVita (DVA) Could Be Positioned for a Surge

Rite Aid

Tempur Sealy International

Twin River Worldwide Holdings Inc

United Therapeutics

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

5 Stocks in Focus on Remarkable Relative Price Strength

Cardinal Health

Legg Mason

McKesson

PG&E

PEG-based investing can be more rewarding with the addition of a few other relevant parameters.

5 Great GARP Stocks Based on Discounted PEG

Ensign Group

KalVista Pharma

MEI Pharma

ResMed

Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.

New Covid-19 Cases Increase, 5 Defensive Stocks to Buy

DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can DaVita HealthCare (DVA) Run Higher on Rising Earnings Estimates?

First Eagle Investment (Trades, Portfolio) disclosed this week that its buys during the fourth quarter of 2019 included a new position in DaVita Inc.

First Eagle Buys Buffett’s DaVita in the 4th Quarter

DaVita (DVA) gains from dialysis services in the United States in Q4.

DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss

The dialysis services provider beat Wall Street earnings estimates in Q4 but narrowly missed revenue expectations.

What's Behind DaVita's Mixed Q4 Results

DaVita Inc. (DVA) CEO Javier Rodriguez on Q4 2019 Results - Earnings Call Transcript

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 12.05% and -0.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

DaVita HealthCare (DVA) Tops Q4 Earnings Estimates

DaVita (NYSE: DVA) reported quarterly earnings of $1.86 per share on Monday, which beat the analyst consensus estimate of $1.66.

DaVita Reports Q4 Earnings Beat, Raises Guidance

DaVita (DVA) expects to have gained from calcimimetics in the fourth quarter.

What's in the Cards for DaVita (DVA) This Earnings Season?

DaVita HealthCare (DVA) closed at $82.03 in the latest trading session, marking a -1.39% move from the prior day.

DaVita HealthCare (DVA) Stock Moves -1.39%: What You Should Know

Davita Inc (NYSE: DVA) surged to all-time highs Friday after winning the praise of a new market advocate.

Goldman Sachs Upgrades Davita, Poised To Profit From Medicare Expansion

DaVita HealthCare (DVA) closed the most recent trading day at $79.47, moving +0.61% from the previous trading session.

DaVita HealthCare (DVA) Outpaces Stock Market Gains: What You Should Know

Amedisys

Hanger Inc

Rosy Outlook for Outpatient and Home Healthcare Industry

America's Car-Mart

Guardant Health Inc

Lithia Motors

Sonic Automotive

U.S. Consumer spending rises in November and with consumer sentiments' higher in December, these five stocks are a good buy.

U.S. Consumer Spending Bolsters Economic Growth: 5 Picks

DaVita HealthCare (DVA) closed the most recent trading day at $73.75, moving +0.41% from the previous trading session.

DaVita HealthCare (DVA) Gains But Lags Market: What You Should Know

LHC Group

Select Medical Holdings

Increasing incidence of chronic diseases, aging U.S. population, innovation and consolidation will drive the healthcare industry's growth in 2020.

5 Healthcare Stocks to Keep the Winning Streak Alive in 2020

This kidney dialysis company has attracted the attention of a well-known short seller.

A Warren Buffett Investment That You Don’t Want To Own

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

Why Is DaVita HealthCare (DVA) Up 2.9% Since Last Earnings Report?

The healthcare provider reported a much-needed strong quarter, which got the stock moving higher again.

Why DaVita Stock Surged 22% in November

DaVita Inc.(NYSE: DVA) is a medical services company providing kidney dialysis services to patients in the United States as well as internationally.

Identifying Key Factors Responsible For The 25% Jump In DaVita’s Stock This Month

Tenet Healthcare

Prominent activities in the healthcare sector are pushing the sector ahead this quarter.

4 Healthcare Stocks to Gain From Stellar Q3 Earnings

Garmin

Ultra Clean

Top Ranked Momentum Stocks to Buy for November 22nd

News for DaVita Stock (DVA)